This Week in Psychedelics - 1.28.22

Cannabis

  • Thailand Becomes First Country in Asia to Decriminalize Marijuana (TIME)

  • New York medical cannabis approved for ‘any’ condition a doctor recommends (Leafly)

  • Mississippi: Lawmakers Advance Medical Cannabis Access Bill to Governor’s Desk (NORML)

  • Amazon Endorses Federal Cannabis Legalization (High Times)

  • Europeans choosing cannabis over ecstasy (The Portugal News)

  • Delaware Lawmakers Approve Marijuana Legalization Bill In Committee Vote (Marijuana Moment)

  • Arkansas voters could see 3 recreational marijuana initiatives on ballot (Marijuana Business Daily)

  • Cannabis Events Come Out of Hiding in New York City (The New York Times)

  • North Dakota recreational marijuana measure fails to qualify for ballot (Marijuana Business Daily)

  • Wisconsin Republicans Announce Limited Medical Marijuana Legalization Bill (Marijuana Moment)

  • Legal Cannabis Opens a Pandora’s Box of Equity Issues (Capital and Main)

  • Ohio Lawmakers Will Be Forced To Consider Marijuana Legalization As State Validates Activist Signatures (Marijuana Moment)

  • Active Ingredient in Cannabis Protects Aging Brain Cells (Neuroscience News)

  • Majority Of Americans Say They’d Vote For A Politician Who Smokes Marijuana, Poll Finds (Marijuana Moment)

  • What Happens When You Quit Cannabis? (IFLScience)

  • Missouri Marijuana Legalization Measures Take Differing Approaches to Expungement (Marijuana Moment)

  • Minnesota Groups Bind Together to Oppose Legal Cannabis (High Times)

  • Don’t Feed Marijuana Buds To Donkeys, New Study Warns (Marijuana Moment)

  • South Dakota: House Lawmakers Move to Repeal Citizen-Initiated Home Cultivation Rights (NORML)

LSD

  • FDA clears phase 2b study of LSD treatment for generalized anxiety (Healio)

Magic Mushrooms

  • No difference between psilocybin microdosing and placebo, trial finds (New Atlas)

  • Colorado Activists File Revised Ballot Initiatives To Legalize Psilocybin And Establish ‘Healing Centers’ (Marijuana Moment)

  • Oregon Lawmakers File Psilocybin Equity Bill As State Implements Legal Use Program (Marijuana Moment)

  • Oklahoma Republicans File Bills To Decriminalize Psilocybin And Encourage Research On Medical Benefits (Marijuana Moment)

  • Numinus Identified as a Licensed Psilocybin Supplier by Health Canada (Psilocybin Alpha)

  • Psilocybin: Following in the Footsteps of Cannabis Along the Path to Legality (JD Supra)

  • Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada (Psilocybin Alpha)

  • How is Oregon Preparing for the Facilitated Use of Psilocybin? (Lucid News)

  • Red Light Holland’s Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program (Psilocybin Alpha)

  • Diamond Therapeutics Looks At Low-Dose Psilocybin (The Dales Report)

  • Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans (Psilocybin Alpha)

DMT

  • Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property (Psilocybin Alpha)

5-MeO-DMT

  • A Psychedelic Craze Has Taken Hold Among The Rich, Toad Venom (Baller Alert)

Novel Psychoactive Substances

  • The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (VICE)

  • Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions (Psilocybin Alpha)

Ketamine

  • New study indicates ketamine is less effective than electroconvulsive therapy for severe depression (PsyPost)

  • Ketamine Intravenous Therapy Shown to Improve Depression, Reduce Suicidal Ideation (Psych Central)

  • Have We Eliminated Stigma Surrounding Ketamine-Assisted Treatment? (Volteface)

Miscellaneous

  • Missouri Legislators Introduce Bill to Give Terminally Ill Patients Access to Psychedelics (DoubleBlind)

  • Virginia House Committee Pushes Back Psychedelics Decriminalization Bill Until 2023, But Senate Proposal Still Pending (Marijuana Moment)

  • Lawmakers Propose Study of Natural Psychedelics for Mental Health Use (Westword)

  • Introducing Vital: Immersive, Inclusive, and Personal Psychedelic Training for Professionals (Psychedelics Today)

  • Psychedelic Perceptions in 2021: Popular Culture & Controversy (Psilocybin Alpha)

  • Family Tripping: How Multigenerational Psychedelic Drug Experiences Can Provide Connection (Everything Zoomer)

  • Psychedelic Capital: Public vs. Private Markets (Truffle Report)

  • Sensible policy on psychedelic drugs is growing more common (The Economist)

  • Inside the Growing Wellness Trend of Psilocybin Mushroom Microdosing (The Hollywood Reporter)

  • Hallucinogen chemistry guides antidepressant drug discovery (Chemical and Engineering News)

  • Decriminalize Nature and Students For Sensible Drug Policy Create a Community Healing Alliance (High Times)

  • Have You Taken Psychedelics? Participate In The Canadian Psychedelics Survey Sponsored By MAPS PBC (The Dales Report)

  • Laganja Estranja’s Psychedelic Life (DoubleBlind)

  • Psychedelics and Parkinson’s Disease: Improving Patient Quality of Life (Truffle Report)

  • Psychedelic and Plant Medicines: A Portal to Transformative Realms of Possibility (Nonprofit Quarterly)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.